Adtran unlocks full potential of ZR and ZR+ optics with FSP 3000 M-Flex800™
21.3.2024 16:00:00 EET | Business Wire | Press release
Adtran today launched its FSP 3000 M-Flex800™, enabling network operators to unlock the full potential of ZR and ZR+ optics for high-capacity transport solutions across edge, metro and core networks. This single-slot card – the newest addition to Adtran’s coherent optical technology suite – offers a universal host for ZR and ZR+ optics and addresses many of the shortfalls of IP-over-DWDM (IPoWDM) solutions. Compared to classical OTN muxponder solutions, M-Flex800™ supports much simpler demarcation and multiplexing technology. Combined with the use of a wide range of ZR optics, this enables a new way to develop compact and low-power transport solutions from the edge to the core. This new IP-to-DWDM approach enables flexible, cost-efficient networking with separated IP and optical layers.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240321282596/en/
Adtran’s FSP 3000 M-Flex800™ is a one-slot card that acts as a universal host for ZR, ZR+ and OpenROADM coherent interfaces. (Photo: Business Wire)
“Initially developed for DCI, ZR optics are now expanding their reach into diverse operational environments. Today’s launch will be key in that transition. Our new FSP 3000 M-Flex800™ will be a gateway between classical DWDM and the latest IPoDWDM, bringing the benefits of standardized ZR optics to a broad spectrum of operators,” said Christoph Glingener, CTO of Adtran. “Our versatile one-slot card acts as a universal host for ZR, ZR+ and OpenROADM coherent interfaces, seamlessly integrating into any open line system and enabling multiple use cases. Whether you’re looking to deploy in carrier infrastructure or DCI environments, in central offices or street cabinets, our M-Flex800™ can be easily slotted into any FSP 3000 chassis.”
The Adtran FSP 3000 M-Flex800™ is a versatile, multi-rate line card able to support an extensive range of grey and coherent interfaces, including 100Gbit/s, 400Gbit/s, 800Gbit/s, ZR, ZR+, OpenROADM and other types of coherent optics. Designed to meet the high-capacity connectivity needs of telecom operators, cloud providers and enterprises, it facilitates a range of applications from the edge to the core. This universal host simplifies upgrades to 800Gbit/s line speeds and Ethernet services and can multiplex 100GbE, 400GbE and OTU4 services into line speeds up to 800Gbit/s. Suited for tasks such as IP and optical demarcation, ZR-to-ZR interconnects and edge OTN applications, the Adtran FSP 3000 M-Flex800™ offers a cost-effective and low-power solution in a single-slot card.
“With its exceptional flexibility, operational simplicity and compact footprint, our FSP 3000 M-Flex800™ caters to diverse environments, from data centers to space-restricted street cabinets. Its ability to reduce power consumption while supporting high-capacity, open and scalable transport is a testament to our commitment to driving the next generation of transport infrastructure,” commented Ryan Schmidt, GM of optical transport at Adtran. “We’re addressing the core needs of network operators across a broad spectrum of applications, even beyond the traditional transponder/muxponder use cases. Today’s launch marks a big step towards more efficient, versatile and cost-effective infrastructure.”
Further information on the FSP 3000 M-Flex800™ is available in these slides.
A supporting product video is also available to watch.
About Adtran
ADTRAN Holdings, Inc. (NASDAQ: ADTN and FSE: QH9) is the parent company of Adtran, Inc., a leading global provider of open, disaggregated networking and communications solutions that enable voice, data, video and internet communications across any network infrastructure. From the cloud edge to the subscriber edge, Adtran empowers communications service providers around the world to manage and scale services that connect people, places and things. Adtran solutions are used by service providers, private enterprises, government organizations and millions of individual users worldwide. ADTRAN Holdings, Inc. is also the largest shareholder of Adtran Networks SE, formerly ADVA Optical Networking SE. Find more at Adtran, LinkedIn and X.
Published by
ADTRAN Holdings, Inc.
www.adtran.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240321282596/en/
Contact information
For media
Gareth Spence
+44 1904 699 358
public.relations@adtran.com
For investors
Steven Williams
+49 89 890 665 918
investor@adtran.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IQM Appoints Craig Ciesla, Former Illumina VP, as CTO; Inés de Vega Becomes Chief Scientist19.6.2026 10:00:00 EEST | Press release
IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointments of Dr. Craig Ciesla as Chief Technology Officer (CTO) and Dr. Inés de Vega as Chief Scientist, as she transitions from her role as Vice President of Quantum Solutions, deepening IQM´s leadership as the company prepares for its planned Nasdaq listing through a merger with Real Asset Acquisition Corp. (Nasdaq: RAAQ). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260619693929/en/ From left to right: Dr. Inés de Vega, Chief Scientist, and Dr. Craig Ciesla, Chief Technology Officer. Ciesla, an experienced deep tech executive with more than 25 years delivering products across multiple industries from startups to Fortune 500 companies, will advance IQM's technology strategy and drive its implementation into systems and products. De Vega, meanwhile, will be responsible for ensuring scientific feasibility and system-level
Teijin Receives Approval for Additional Indications of XEOMIN ® for Cervical Dystonia and Blepharospasm in Japan19.6.2026 10:00:00 EEST | Press release
Teijin Pharma Limited, the core company of the Teijin Group’s healthcare business, and Merz Therapeutics GmbH, a leading player in neurology-focused specialty pharma, jointly announced today that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved the additional indications for XEOMIN® (incobotulinumtoxinA) for the treatment of cervical dystonia and blepharospasm. This approval represents the fourth and fifth indications for XEOMIN® authorized in Japan, alongside its existing approvals for the treatment of upper limb spasticity, lower limb spasticity and chronic sialorrhea. Cervical dystonia is a focal dystonia characterized by involuntary contractions of the neck muscles, resulting in abnormal or repetitive movements and postures.1 Blepharospasm is also a focal dystonia, characterized by excessive involuntary contractions of the muscles surrounding the eye.2 Both conditions significantly impact patients’ quality of life. The approval by MHLW is based on Phase III clinic
Incyte Japan Announces Approval of Minjuvi ® (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)19.6.2026 09:00:00 EEST | Press release
Incyte Biosciences Japan G.K. today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved Minjuvi® (tafasitamab) in combination with lenalidomide for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). “This approval provides a new option for patients in Japan living with relapsed or refractory DLBCL, an aggressive disease with historically limited treatment options,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “We are committed to helping address critical unmet needs for patients and their families affected by this challenging cancer.” DLBCL is the most common subtype of non-Hodgkin lymphoma and is an aggressive malignancy of B lymphocytes. While many patients respond to initial therapy, outcomes remain poor for those with relapsed or refractory disease, particularly for patients who are not eligible for autologous stem cell transplant.1 The approval is based on results from the MOR208C203 Trial: L
Amazfit Introduces Helio Strap Pro, Bringing Body-Worn Movement Intelligence to HYROX and Hybrid Training18.6.2026 20:07:00 EEST | Press release
Amazfit, a leading global smart wearable brand owned by Zepp Health (NYSE: ZEPP), today announced Helio Strap Pro, a body-worn training system designed to help HYROX and hybrid athletes better understand how their bodies perform under load. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260618031434/en/ Amazfit Introduces Helio Strap Pro, Bringing Body-Worn Movement Intelligence to HYROX and Hybrid Training Building on the screen-free Helio Strap, Helio Strap Pro adds a dedicated waist-mounted motion sensor that captures core-body movement and stability during training. Combined with upper-arm heart-rate sensing and compatible Amazfit smartwatches, the system provides a more complete picture of cardio effort, movement quality and muscle load than wrist-based tracking alone. Helio Strap Pro represents the next evolution of Amazfit's Hybrid Training System, extending performance tracking beyond heart rate to help athletes bett
HyperLight Announces $80 Million Series C to Accelerate TFLN Deployment for AI Infrastructure18.6.2026 18:30:00 EEST | Press release
HyperLight Corporation (“HyperLight”), a leader in thin-film lithium niobate (TFLN) photonics, today announced the closing of an $80 million Series C financing round led by MediaTek. The round includes participation from UMC Capital, Jabil, Foxconn, EDBI (arm of SG Growth Capital, the investment platform of the Singapore Economic Development Board and Enterprise Singapore), CDIB-TEN Capital, and Qatar Investment Authority (QIA), as well as strategic investors from leading silicon IC and networking companies. Existing investors Summit Partners, The Engine, Foothill Ventures, and Xora Innovation continue to actively support the company’s growth. The financing brings together companies across the AI infrastructure value chain — including silicon ICs, foundry manufacturing, electronics manufacturing services, networking, and global infrastructure investment — reflecting broad ecosystem support for scaling TFLN photonics into production. “This financing is about more than capital — it is ab
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
